Advancing AAV Gene Therapies: Insights from CURE Epilepsy-Funded Research

This investigators workshop examines adeno-associated virus gene therapies for epilepsy from design and animal testing through clinical translation. Research examples concern Lafora disease, SCN1B-related Dravet syndrome and SLC6A1-related neurodevelopmental disorder. The panel considers treatment efficacy, seizure-associated adverse effects and AAV toxicity, alongside strategies for overcoming current limitations. Discussion also covers biomarkers, scalability and the evidence needed to advance candidates beyond preclinical studies.

Sunday 6 December, 14:00–15:30 Mountain Standard Time (America/Denver). Part of the 2026 American Epilepsy Society Annual Meeting. In-person meeting registration and a free myAES account are required. Standard full-meeting rates are USD 800 for member scientists and USD 1,075 for non-member scientists; student rates are USD 250 and USD 360, respectively. Other professional and one-day categories are available. Seating priority goes to registered attendees.